Celldex (CLDX) Prices Upsized 5.95M Share Offering at $42/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- S&P 500, Nasdaq set to open higher as AI stocks rebound ahead of earnings rush
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month high with Hormuz transits in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- S&P 500, Nasdaq set to open higher as AI stocks rebound ahead of earnings rush
- Glass House Brands posts Q3 revenue of $56.8M, board member exits
- Microsoft pulls out of UK Nscale data centre deal over power delay
- Eos Energy Q3 2026 preliminary revenue up 169% year over year
Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock
July 13, 2021 8:30 PM EDTHAMPTON, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Celldex or the Company) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common stock at a public offering price of $42.00 per share. In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 892,857 shares of common stock at the public offering price, less underwriting discounts and commissions.
Jefferies, SVB Leerink, Guggenheim Securities and Cantor are acting as the joint book-running managers for the offering. LifeSci... More



